HEALTH.2010.2.3.3-4: Novel therapeutics against influenza. FP7-INFLUENZA-2010.
Research should address the need for novel therapeutic options against influenza. This could encompass the development of drugs against viral targets as well as drugs interfering with host-response pathways that play a role in the development of the disease. Passive immunotherapy or combination therapy could also be considered under this topic. One or several of these different approaches could be envisaged in each proposal. During project duration, the stages of proof-of-concept in animal models, safety and toxicology profiles and possibly first clinical studies should be reached. Active participation of SMEs could lead to an increased impact of the research proposed and will be considered in the evaluation of the proposal. The essential integration of SMEs in view of route-to-market considerations and the relevant intellectual property management needs to be clearly addressed in the proposal.
Note: Limits on the EC financial contribution apply. These are implemented strictly as formal eligibility criteria. You must refer to the call fiche for details of these limits.
Funding scheme: Collaborative projects (Small or medium-scale focused research project)
EC contribution per project: max. EUR 6 000 000
One or more proposals can be selected.
Expected impact: Projects are expected to pave the way for the development of new and alternative treatment options, with the aim of reinforcing the necessary therapeutic arsenal for control of influenza outbreaks. This will improve the protection of populations in Europe (and worldwide) against potential new pandemics as well as offer alternative treatment options for patients vulnerable to seasonal influenza. The results of these projects will in particular provide alternative management options for viral strains resistant to currently available antiinfluenza drugs. The project will also contribute to increasing European competitiveness in the pharmaceutical sector.